A new Omicron subvariant is taking over in the United States according to mainstream media and health “experts.” It’s called XBB 1.5 and is making up 44% of the COVID-19 cases in the U.S.

XBB has been found in at least 70 countries, according to the World Health Organization, and has caused surges of infection in some parts of Asia, including India and Singapore, in October.

The XBB.1.5 is a relative of the omicron XBB variant, which is a recombinant of the omicron BA.2.10.1 and BA.2.75 subvariants, according to the World Health Organization.  Combined, XBB and XBB.1.5 make up 44% of cases in the U.S., crowding out other versions of omicron. Apparently, the ruling class has yet to decide if the new variant evades the “immunity” offered by the “vaccines.”

Studies performed in the lab have found that XBB is capable of evading antibodies from previous Covid infections or vaccinations, meaning that being exposed to the virus would mean someone is more likely to get sick or reinfected and show symptoms. That means that the shots don’t matter and those fully vaccinated people are just as susceptible to getting this and the unvaccinated.

Yet, in the meantime, India claims they don’t have to worry, since the whole population has pretty much been naive enough to get injected with the experimental gene therapy shots:

India does not have to worry about the new Covid variant of XBB.1.5 as 90% of its eligible population has been vaccinated 30-40% have administered booster doses, said Dr. M Wali, Physician in Sir Ganga Ram Hospital in New Delhi. -Mint

Studies performed in the lab have found that XBB is capable of evading antibodies from previous Covid infections or vaccinations, meaning that being exposed to the virus would mean someone is more likely to get sick or reinfected and show symptoms.

“It’s clear that there’s immune evasive properties of XBB,” said Dr. Isaach Bogoch, an infectious disease physician and epidemiologist at the University of Toronto. “That’s been demonstrated both in laboratory studies and seen clinically in cases and hospitalizations.”

The goal is to continue to try to convince people to get injected with as many shots as possible. As NBC News wrote: The new XBB.1.5 variant was not studied in the report, but Suthar predicts its immune evasive properties to be in a similar range as XBB. He expects the bivalent booster will bolster protection against the latest version as well.